PHARMACOKINETICS OF FLUCONAZOLE IN VERY-LOW-BIRTH-WEIGHT INFANTS DURING THE 1ST 2 WEEKS OF LIFE

被引:98
作者
SAXEN, H
HOPPU, K
POHJAVUORI, M
机构
[1] Children's Hospital, University of Helsinki
关键词
D O I
10.1038/clpt.1993.147
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To find a dose of fluconazole for very low birth weight infants during an outbreak of Candida parapsilosis. Methods: Twelve premature infants (mean gestational age, 27.4 weeks; mean birth weight, 912 gm) receiving fluconazole prophylactically from the first day of life were enrolled in an open phase I-II pharmacokinetics, safety, and tolerance trial. Up to 5 doses of 6 mg/kg were administered intravenously every 72 hours during the first 2 weeks of life. Pharinacokinetic characteristics of fluconazole were determined after the first, third, and fifth doses. Results: The mean peak and trough concentrations after the 3 doses were 5.5 and 2.6 mug/ml, 12.8 and 4.3 mug/ml, and 10.0 and 2.9 mug/ml (p = 0.0002 and p = 0.07), respectively. The mean fluconazole half-lives were 88.6 hours (n = 7), 67.5 hours (n = 9), and 55.2 hours (n = 4; p = 0.3). The mean total clearance corrected for weight (CL/kg) was 0.18 ml/min/kg (n = 7), 0.33 ml/min/kg (n = 7), and 0.52 ml/min/kg (n = 4; p = 0.02), and the mean volume of distribution 1.18 L/kg (n = 7), 1.84 L/kg (n = 7), and 2.25 L/kg (n = 4; p = 0.05). Weight-corrected clearance increased with postnatal age (r = 0.61; p = 0.007). Conclusions: With the used fluconazole dose (6 mg/kg every 3 days), the mean serum peak and trough concentrations increased during the first week but decreased during the second week. After the first week we suggest a dose of 6 mg/kg every 2 days, or even daily.
引用
收藏
页码:269 / 277
页数:9
相关论文
共 15 条
[1]   DEVELOPMENTAL PATTERNS OF RENAL FUNCTIONAL MATURATION COMPARED IN HUMAN NEONATE [J].
ARANT, BS .
JOURNAL OF PEDIATRICS, 1978, 92 (05) :705-712
[2]   PHARMACOKINETICS, OUTCOME OF TREATMENT, AND TOXIC EFFECTS OF AMPHOTERICIN-B AND 5-FLUOROCYTOSINE IN NEONATES [J].
BALEY, JE ;
MEYERS, C ;
KLIEGMAN, RM ;
JACOBS, MR ;
BLUMER, JL .
JOURNAL OF PEDIATRICS, 1990, 116 (05) :791-797
[3]  
BALEY JE, 1986, PEDIATRICS, V78, P225
[4]  
BRAMMER KW, 1991, DRUG METAB DISPOS, V19, P764
[5]   CLINICAL PHARMACOKINETICS OF FLUCONAZOLE [J].
DEBRUYNE, D ;
RYCKELYNCK, JP .
CLINICAL PHARMACOKINETICS, 1993, 24 (01) :10-27
[6]  
Gibaldi M., 1984, BIOPHARMACEUTICS CLI
[7]   FLUCONAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN SUPERFICIAL AND SYSTEMIC MYCOSES [J].
GRANT, SM ;
CLISSOLD, SP .
DRUGS, 1990, 39 (06) :877-916
[8]   PHARMACOKINETIC EVALUATION OF UK-49,858, A METABOLICALLY STABLE TRIAZOLE ANTIFUNGAL DRUG, IN ANIMALS AND HUMANS [J].
HUMPHREY, MJ ;
JEVONS, S ;
TARBIT, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (05) :648-653
[9]  
JOHANSON DE, 1984, PEDIATRICS, V73, P138
[10]   POSTCONCEPTIONAL AGE AND GENTAMICIN ELIMINATION HALF-LIFE [J].
KASIK, JW ;
JENKINS, S ;
LEUSCHEN, MP ;
NELSON, RM .
JOURNAL OF PEDIATRICS, 1985, 106 (03) :502-505